MRV is a multisite collaboration of clinical and non-clinical researchers, cohort participants and consumers.
Publications
Immune checkpoint inhibitors for cancer and venous thromboembolic events
BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments.
Declining cancer incidence in the elderly: decreasing diagnostic intensity or biology?
BACKGROUND: Advanced age is a consistent risk factor for cancer, nonetheless cancer incidence typically declines after age 75-85 for most solid tumors.
FDA Grants Fast Track Status to UVI Plus Checkpoint Inhibition for Melanoma Subgroup
The FDA has granted a fast track designation to UV1, a universal cancer vaccine, in combination with either pembrolizumab (Keytruda) or…